Your browser is no longer supported. Please, upgrade your browser.
KALA Kala Pharmaceuticals, Inc. monthly Stock Chart
KALA [NASD]
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own0.20% Shs Outstand56.95M Perf Week18.56%
Market Cap498.31M Forward P/E- EPS next Y-1.48 Insider Trans- Shs Float53.99M Perf Month38.89%
Income-94.30M PEG- EPS next Q-0.52 Inst Own68.00% Short Float12.97% Perf Quarter128.46%
Sales6.10M P/S81.69 EPS this Y-10.60% Inst Trans29.66% Short Ratio5.00 Perf Half Y116.05%
Book/sh0.85 P/B10.29 EPS next Y24.50% ROA-54.60% Target Price17.33 Perf Year2.70%
Cash/sh1.50 P/C5.84 EPS next 5Y- ROE-174.60% 52W Range3.24 - 9.66 Perf YTD137.13%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-87.40% 52W High-9.37% Beta-
Dividend %- Quick Ratio4.10 Sales past 5Y67.90% Gross Margin66.90% 52W Low170.06% ATR0.91
Employees136 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)65.97 Volatility11.80% 16.61%
OptionableYes Debt/Eq0.00 EPS Q/Q16.90% Profit Margin- Rel Volume0.65 Prev Close8.97
ShortableYes LT Debt/Eq2.40 EarningsMay 13 BMO Payout- Avg Volume1.40M Price8.75
Recom1.30 SMA2018.64% SMA5028.38% SMA20071.63% Volume910,129 Change-2.45%
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Apr-03-20 04:01PM  Kala Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-20-20 08:30PM  13D Filings Barrons.com
Mar-15-20 04:24PM  Insiders Roundup: Masimo, Hertz GuruFocus.com
Mar-11-20 11:06AM  Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More Zacks
10:50AM  Oppenheimer: These 3 Stocks Are Ripe for Double-Digit Gains TipRanks
Mar-10-20 11:02PM  Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock Business Wire
04:44PM  Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
11:30AM  Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year? Zacks
09:31AM  Kala Pharmaceuticals, Inc. (KALA) Shares March Higher, Can It Continue? Zacks
09:24AM  Top Ranked Momentum Stocks to Buy for March 10th Zacks
Mar-09-20 06:00AM  Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS for Signs and Symptoms of Dry Eye Disease Business Wire +26.27%
Mar-06-20 10:11AM  Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Feb-20-20 04:01PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-12-20 11:30AM  Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year? Zacks
08:35AM  Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-09-20 03:22PM  The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight Benzinga
Feb-06-20 11:53AM  Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan Zacks +9.74%
08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call Business Wire
Feb-03-20 11:11AM  Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks +8.89%
Jan-30-20 11:10AM  Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-22-20 09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks +5.30%
09:33AM  3 Healthcare Stocks With Important Catalysts in Q1 TipRanks
Jan-15-20 08:00AM  Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS (KPI-121 0.25%) for Dry Eye Disease Business Wire
Jan-14-20 09:21AM  Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 13% Simply Wall St.
Jan-08-20 08:00AM  Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire +9.28%
Dec-19-19 09:53PM  Is Kala Pharmaceuticals, Inc. (KALA) A Good Stock To Buy? Insider Monkey
04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-12-19 04:11PM  3 Biotech Stocks That Offer the Highest Upside on Wall Street TipRanks +12.86%
Nov-19-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-07-19 08:25AM  Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
Nov-04-19 04:30PM  Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-21-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-11-19 08:34AM  What Kind Of Shareholders Own Kala Pharmaceuticals, Inc. (NASDAQ:KALA)? Simply Wall St.
Sep-25-19 08:40AM  Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Sep-19-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-29-19 08:00AM  Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-27-19 08:56AM  A Holistic Look At Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Simply Wall St. -6.54%
Aug-23-19 11:24AM  Keep Your Eye on These 4 Healthcare Stocks Motley Fool
Aug-20-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-19-19 07:08AM  Should You Buy These 3 Beaten-Down Stocks Now? TipRanks
Aug-08-19 04:01PM  Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial Business Wire -9.98%
Aug-06-19 03:40PM  Kala Pharmaceuticals Reports Disappointing Q2 Sales Motley Fool -13.27%
02:23PM  Kala Pharmaceuticals, Inc. (KALA) Q2 2019 Earnings Call Transcript Motley Fool
09:45AM  Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results Business Wire
Jul-30-19 04:05PM  Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call Business Wire
Jul-22-19 08:02AM  How Does Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Affect Your Portfolio Volatility? Simply Wall St.
Jun-20-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-13-19 03:11PM  Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven Simply Wall St.
May-30-19 08:00AM  Kala Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference Business Wire
May-17-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-16-19 02:15PM  Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 08:15AM  Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:08AM  Kala Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
May-02-19 08:00AM  Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call Business Wire
Apr-29-19 08:59AM  Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock? Zacks
Apr-25-19 11:35AM  Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 52% Simply Wall St.
Apr-18-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-01-19 08:00AM  Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-14-19 10:24AM  Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Mar-11-19 04:12PM  Kala Pharma: 4Q Earnings Snapshot Associated Press +6.03%
04:01PM  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Mar-06-19 08:00AM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March Business Wire -7.92%
Mar-04-19 08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call Business Wire
Feb-22-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +5.16%
Jan-18-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-07-19 07:00AM  Kala Pharmaceuticals Announces the Launch of INVELTYS and the Hiring of a Specialty Ophthalmology Sales Organization Business Wire +6.17%
Jan-04-19 07:52AM  Kala Pharmaceuticals, Inc.s (NASDAQ:KALA) Path To Profitability Simply Wall St. +12.12%
Jan-02-19 08:00AM  Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference Business Wire +6.13%
Dec-28-18 07:20AM  Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-26-18 07:00AM  Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration Business Wire
Dec-19-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-23-18 08:00AM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-08-18 07:56AM  Kala Pharma: 3Q Earnings Snapshot Associated Press
07:30AM  Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results Business Wire
Nov-07-18 04:05PM  Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Business Wire
Oct-25-18 08:00AM  Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs Business Wire
Oct-24-18 08:55AM  New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -10.19%
Oct-19-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-18-18 08:00AM  Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO Business Wire
Oct-16-18 08:00AM  Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease Business Wire +10.94%
Oct-11-18 04:01PM  Kala Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-09-18 08:44AM  Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4% Zacks
Oct-03-18 11:58AM  Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today Motley Fool -15.52%
Oct-02-18 04:18PM  Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:18PM  Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million Business Wire
Sep-26-18 12:50PM  Is Kala Pharmaceuticals Incs (NASDAQ:KALA) Balance Sheet A Threat To Its Future? Simply Wall St. -8.09%
Sep-21-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Aug-31-18 07:50AM  Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:01PM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
09:38AM  Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA Zacks
Aug-23-18 03:28PM  U.S. FDA approves Kala Pharma's eye pain drug Reuters -7.20%
02:13PM  Kala stock declines 6% after FDA approves ocular surgery product MarketWatch
Aug-16-18 10:06AM  H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date SmarterAnalyst +6.50%
Aug-09-18 07:48AM  Kala Pharma: 2Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen HongmingChief Scientific OfficerMar 30Option Exercise2.3031,00071,30086,849Apr 01 04:43 PM
Bazemore ToddChief Operating OfficerMar 16Buy5.7510,00057,50010,000Mar 17 05:46 PM
Grunberg GregoryDirectorMar 13Buy7.892,534,85419,999,9982,534,854Mar 16 07:59 AM
Shah Rajeev M.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:45 PM
Rosen Howard BDirectorMay 30Buy5.425,00027,1008,240Jun 03 10:41 AM